In vivo myocardial distribution of multipotent progenitor cells following intracoronary delivery in a swine model of myocardial infarction

Hung Q. Ly1,4*, Kozo Hoshino1, Irina Pomerantseva3,1, Yoshiaki Kawase1, Ryuichi Yoneyama1, Yoshiaki Takewa1, Annik Fortier4, Summer L. Gibbs-Strauss2, Carrie Vooght2, John V. Frangioni2, and Roger J. Hajjar1

1Mount Sinai School of Medicine, New York, NY, USA; 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 3Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; and 4Department of Medicine, Montreal Heart Institute, Université de Montréal, 5000 Belanger Street (east), Montréal, QC, Canada

Received 21 July 2008; revised 16 June 2009; accepted 24 July 2009; online publish-ahead-of-print 17 August 2009

Aims There are few data comparing the fate of multipotent progenitor cells (MPCs) used in cardiac cell therapy after myocardial infarction (MI). To document in vivo distribution of MPCs delivered by intracoronary (IC) injection.

Methods and results Using an anterior MI swine model, near-infrared (NIR) fluorescence was used for in vivo tracking of labelled MPCs [mesenchymal stromal (MSCs), bone marrow mononuclear (BMMNCs), and peripheral blood mononuclear (PBMNCs)] cells early after IC injection. Signal intensity ratios (SIRs) of injected over non-injected (reference) zones were used to report NIR fluorescence emission. Following IC injection, significant differences in mean SIR were documented when MSCs were compared with BMMNCs [1.28 ± 0.10 vs. 0.77 ± 0.11, P < 0.001; 95% CI (0.219, 0.805), respectively] or PBMNCs [1.28 ± 0.10 vs. 0.80 ± 0.14, P = 0.005; 95% CI (0.148, 0.813), respectively]. Differences were maintained during the 60 min tracking period, with only the MSC-injected groups continuously emitting NIR fluorescence (SIR > 1). This is correlated with greater cell retention for MSCs relative to mononuclear cells. However, there was evidence of MSC-related vessel plugging in some swine.

Conclusion Our in vivo NIR fluorescence findings suggest that MPC distribution and retention immediately after intracoronary delivery vary depending on cell population and could potentially impact the clinical efficacy of cardiac cell therapy.

Keywords In vivo • Multipotent progenitor cells • Intracoronary • Myocardial infarction • Near-infrared fluorescence

Introduction

Cell-based therapy for myocardial repair has recently garnered a great deal of interest, emerging as a promising adjunctive therapy for ischaemic heart disease.1–3 A growing body of evidence has alluded to its beneficial role in the setting of myocardial infarction (MI).4,5 A rapid transition towards clinical application has lead to cautious optimism but has prompted a call for further translational research using clinically relevant large animal models to clarify the contributions of multipotent progenitor cells (MPCs).5,6 As such, tracking the biological fate of these cells remains a pivotal issue. Near-infrared (NIR) fluorescence imaging, an established in vivo molecular imaging modality, could be used to track transplanted MPCs.7,8 Cell retention after intracoronary (IC) injection may be altered not only due to the injured cardiac milieu, but also because MPCs vary in their ability to home and engraft to the latter. Thus, we hypothesize that, in the immediate phase after IC delivery, the in vivo myocardial distribution and retention in infarcted myocardium will differ depending on the MPC population.

Methods

Intracoronary delivery of MPCs was compared in the setting of infarcted myocardium. A total of 15 swine were included in the study; three expired at the time of MI model creation. Of the remainder, 12 swine
were equally divided into three study groups: mesenchymal stem cells (MSCs), bone marrow mononuclear cells (BMMNCs), and peripheral blood mononuclear cells (PBMCs). Every third swine was assigned, in a non-randomized fashion, to a specific cell injection group. A decision was made a priori to limit this study to 15 swine for budgeting reasons. Institutional committees on research animal care approved the study protocol. All study animals received humane care in accordance with the Principles of Laboratory Animal Care (National Society of Medical Research) and the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources and the National Institutes of Health).

Isolation of multipotent progenitor cell populations

The collection and isolation methods were chosen to best reflect those used in prior clinical studies of cardiac cell therapy. Please refer to Supplementary material online, Methods for techniques used to harvest PBMCs, BMMNCs, and MSCs.

Myocardial infarction creation and intracoronary cell delivery

Myocardial infarction was created by a 60 min balloon occlusion of the proximal left anterior descending artery (LAD) (Supplementary material online). Study animals were brought back on day 3–4 post-MI for cell injection.

In each study group, a total of $2.0 \times 10^7$ cells were labelled with 1–2 $\mu M$ IR-786 perchlorate (Sigma) diluted in serum-free DMEM, with an incubation time of 20 min at 37°C and 5% CO$_2$ (Figure 1A and B). IR-786-loaded cells were examined under NIR fluorescence microscopy to ensure successful labelling. For injection, all labelled cells were washed twice with PBS then suspended in a final injection volume of 5 mL of sterile PBS. An over-the-wire balloon catheter system was used for cell delivery and, relying on recorded images during MI creation, the first diagonal in each swine was used as a landmark to position the delivery catheter system. Subsequently, cells were slowly injected (over 3 min) after transient balloon occlusion. Following in vivo MPC tracking, IC administration of cardioplegic solution (Plegisol, Hospira Inc., IL, USA) was used to perform humane euthanasia and hearts were harvested for analyses.

Calibration of near-infrared signal intensity and cell number

To correlate the number of cells retained after delivery and the emitted NIR signal, NIR phantoms were used and calibration curves were constructed as previously described. Briefly, IR-786 loaded MPCs were suspended in a 1 cm path length cuvette at a concentration of $5 \times 10^3$ cells/µL. For our purpose, our correlation studies were performed with only MSCs and mononuclear cells isolated from BM, as PBMCs represent a more lineage-driven, circulating cell population from BMMNCs. Absorbance spectrometry was performed using a HR2000 fibre optic spectrometer and a DH2000-BAL light source (Ocean Optics, Florida). Emitted fluorescence was measured...
after excitation with a NIR light source with defined wavelengths, fluorescence rates, and exposure times. With the latter parameters held constant, the ratio of MPC-related signal intensity (SI) to background could then be translated to absolute cell number. The quantified NIR emissions of each MPC population were subsequently expressed as ‘indocyanine green (ICG) equivalence’ (Figure 1C and D). Such a measure of equivalence will standardize the fluorescence emitted by different MPC populations and, consequently, permits their comparison.

**In vivo near-infrared imaging and fluorescence signal intensity analysis**

For post-injection tracking, *in vivo* open-chest imaging was performed after conventional midline sternotomy to suspend the heart in a peri-cardial cradle and centre the anterior wall of the left ventricle within the imaging field. The in vivo imaging system has been previously described. Briefly, the system is self-contained and mobile thus can be readily positioned over the surgical field for optimal imaging. Separate or merged colour video and fluorescence images are obtained by way of a dichroic mirror, which splits emitted light into visible or NIR light. Every 100 ms, real-time simultaneous anatomic (colour) and functional (NIR fluorescence) imaging data are captured by the respective cameras. Subsequently, measurement of fluorescence SI was done off-line. Quantification of SI was obtained by an operator-determined circumscribed region of interest, which provides SI statistics such as mean, maximum and minimum for the selected area. Assessors who performed imaging analyses were blinded to cell injection group assignments.

Emitted SIs from the myocardial surface were deemed of adequate intensity if documented above background signal noise. Mean SIs were measured at the base (Zone 1; above the first diagonal artery), the mid-LV (Zone 2; between the first diagonal and the terminal bifurcation of the LAD), and the apex (Zone 3; beyond the terminal bifurcation of the LAD) (Figure 2). Serial measurements were made at the following time points: 1 min prior to cell delivery, at 2, 5, 10, 15, 30, 45, and 60 min after injection.

For each time point, a signal intensity ratio (SIR) was calculated (Figure 2). For all computations, as balloon occlusion and MPC injection were performed beyond the first diagonal artery, the base of the heart (Zone 1) was used as the reference zone, whereas the mid-segment and the apex were considered part of the infarcted territory. The SIR was obtained by dividing the mean SI from an infarcted zone by the mean SI from the reference zone, at each time point of the tracking period.

Normalizing the emitted SI using the SIR therefore allows for comparisons between IR-786 labelled MPC groups, as uptake of the fluorophore (and subsequent emitted SIs) may vary according to cell size.

**Statistical analyses**

Continuous variables were reported as mean ± standard error. In order to assess how the SIR change over time, a linear growth model with two covariates (cells, zone) was adjusted using the SAS procedure PROC MIXED. CELLS and ZONE effect were included in a CLASS statement with an ID variable to identify the subject of analysis. Time from injection was considered as a continuum and included in a RANDOM statement, just like the ZONE term and an intercept term. A full model with all the interaction terms (CELLS|ZONE|TIME) was adjusted. In the case of significant interaction, contrasts were used to compare cells groups. All tests were two-sided and a *P*-value less than 0.05 was considered significant. Analyses were performed with SAS (v.9.1.3; SAS Institute Inc., NC, USA).

**Results**

All MPC groups were labelled with the NIR fluorophore IR-786 as described and, by Trypan Blue exclusion test, cell viability for all cell groups was >90% prior to injection. IR-786 loaded cells were found to exhibit NIR fluorescence corresponding to 8.9 and 5.7 attomole equivalents of ICG per MSC and mononuclear cells, respectively.

Following injection after recent infarction, significant differences in mean SIR were documented when MSCs were compared with BMMNCs [1.28 ± 0.10 vs. 0.77 ± 0.11, *P* < 0.001; 95% CI (0.219, 0.805), respectively] or PBMNCs [1.28 ± 0.10 vs. 0.80 ± 0.14, *P* = 0.005; 95% CI (0.148, 0.813), respectively] (Figure 3A).

![Figure 2](https://academic.oup.com/eurheartj/article-abstract/30/23/2861/476353/2863) Near-infrared signal intensity analysis and the signal intensity ratio. The SIR was obtained by dividing the mean SI from a cardiac zone by the mean SI from the reference zone. Since MPC injection occurred at the level of the first diagonal artery, the base of the heart was used as the reference zone, whereas the mid-segment and the apex were (injected) cardiac Zones 2 and 3, respectively. Shown as example is an explanted, uninjured heart after BMMNC delivery (A: colour image; B: NIR image).
This contrast between MSCs and BMMNCs or MSCs and PBMMNCs remained unchanged when MPCs were compared over either the mid- or apical segments (cardiac Zones 2 and 3, respectively) (Figure 3B). Differences between MPCs were maintained over time. While decreases in emitted NIR during in vivo tracking occurred for BMMNCs and PBMMNCs, MSCs always maintained SIR.

Upon IC injection, MPC myocardial distribution closely followed the vascular territory of the LAD (Figure 5A–C). During in vivo monitoring of the anterior wall, with the exception of infarct zones, MPCs appear to distribute homogenously as there were no significant differences in NIR emitted between cardiac Zones 2 and 3 for MSC (mean SIR 1.36 ± 0.11 vs. 1.21 ± 0.11; \(P = 0.07, 95\%\) CI \((-0.01, 0.31)\)), BMMNC (mean SIR 0.85 ± 0.12 vs. 0.69 ± 0.12; \(P = 0.01, 95\%\) CI \((-0.03, 0.34)\)), and PBMMNC (mean SIR 0.86 ± 0.15 vs. 0.74 ± 0.15; \(P = 0.30, 95\%\) CI \((-0.10, 0.34)\)). When examining explanted heart sections, the full thickness of the myocardium was found to be NIR-emitting, thus IR-786 loaded MPCs circulated from the epicardial artery to the microcirculation. However, we also confirmed that MPCs did not permeate scarred areas distribution, likely due to post-infarction microvascular bed injury (Figure 5D). By NIR fluorescence microscopy, NIR-emitting cells could be documented in sections taken only from border and infarct zones of myocardial tissue with very few labelled cells found in the healthy myocardium. The documented progressive decline in SI after injection correlated with declining numbers of retained cell in injured hearts, in both peri-infarct and infarct zones (Figure 5A–C).

Finally, during in vivo MSC tracking, vessel plugging was documented after injection into injured hearts. This did not occur immediately upon cell bolus injection as there was no abrupt cessation of antegrade flow nor was there acute ST-elevation on continuous monitoring as would be expected if embolization occurred during the course of injection. Further, no study animals expired abruptly. Vessel plugging was observed to occur progressively well beyond the first pass and upon recirculation of injected MPCs during the 60 min period of in vivo tracking (Figure 7). This occurred in three swine. This phenomenon was not documented in the mononuclear cell populations.

**Discussion**

Recent trials have reported on the benefits of cell-based therapy as an adjunctive therapy in acute MI. Nevertheless, these findings have been contradicted by findings of equivocal clinical efficacy on cardiac function and structure. \(^{18,19}\) Hence, such contrasting clinical data have prompted a call for further translational research using clinically relevant large animal models with a focus on mechanistic questions in order to push the field forward. \(^{20}\) At the moment, with IC injection into the infarct-related artery being arguably the most widely used route of delivery, there are limited data comparing the myocardial distribution of different MPCs. Our study extends on these findings by providing in vivo data tracking and comparing different MPC populations and how they interact with...
the infarcted microenvironment in the immediate phase after IC injection.

Near-infrared fluorescence imaging has emerged as a promising imaging modality for in vivo tracking of transplanted cells, making use of either organic (e.g. green fluorescence protein, polymethines) or organic/hybrid (quantum dots) exogenous contrast agents. Near-infrared fluorophores (such as IR-786) have high photon absorption and lower tissue scatter than visible wavelengths. In addition, this optical molecular imaging modality is well-suited for conventional microscopy permitting pathological specimen to be scrutinized at the single-cell level. Near-infrared fluorescence offers high sensitivity, provides tomographic imaging capabilities and there is no evidence at present that dye released from dead/dying cells is accumulated by macrophages, a common problem with iron-based MRI contrast agents. Two drawbacks to bear in mind with NIR fluorescence tracking are its fundamental limitation with regard to depth of tissue penetration (1–5 mm for reflectance imaging; 1–4 cm for tomographic imaging) and the dilution of the NIR fluorophore with cell division. The present study lasted 60 min in duration and, as previously

Figure 5 Myocardial distribution of multipotent progenitor cells following intracoronary delivery. Near-infrared imaging data are captured at various tracking time points immediately after intracoronary delivery of MSCs (A), BMMNCs (B), and PBMNCs (C) in the setting of recent infarction. Multipotent progenitor cells readily distribute along the vascular territory of the infarct-related artery. Cell boluses are seen to occupy the intravascular space (top left panel in each figure) and then permeate myocardial tissue after balloon deflation. Shown inset is a colour image of the infarcted heart (B: base; A: apex; Infarct: anterior wall infarct zone); (D) Once injected by intracoronary route, MPCs were documented to penetrate the vascular territory perfused by the left anterior descending artery, in effect permeating the full thickness of the cardiac muscle. In this ‘bread loaf’ section of an infarcted heart after MSC injection, only the scarred area did not show evidence of NIR emission. (A: colour image; B: NIR image; C: merge image; INF: infarct zone; RV: right ventricle; LV: left ventricle).
reported by our group, IR-786 is stable for hours in vivo.\textsuperscript{25} In addition, MPCs were washed thoroughly before injection making the likelihood of dye leakage negligible.

One of the best-characterized NIR fluorophores is ICG, which has a quantum yield of 13\% in dimethylsulfoxide and similar absorption and emission peaks as IR-786. As discussed previously, reporting IR-786 NIR fluorescence intensity as equivalents of ICG fluorescence permits comparison of findings.\textsuperscript{13} In our study, IR-786 loaded MSCs and mononuclear cells exhibited NIR fluorescence equivalent to 8.9 and 5.7 attomole equivalents of ICG per MSC and BM cell, respectively. Thus, NIR fluorophore uptake correlated with cell size and their brightness seen during imaging. Given these values, the high resolution of our NIR fluorescence imaging system, and the low NIR autofluorescence of heart,\textsuperscript{13} it is likely therefore that relatively small numbers of stem cells were detectable in vivo immediately following IC delivery.

Engraftment of delivered MPC remains a daunting challenge, especially in the setting of a hostile, inflammatory microenvironment. There is evidence that the ischaemic myocardial microenvironment is not only conducive but essential in MPC engraftment.\textsuperscript{26,27} Our findings highlight that the injured cardiac milieu alters in vivo MPC retention differently with mononuclear cells rapidly declining or disappearing after injection. Although the phenomenon of recirculation of injected cells could arguably lead to progressively greater cell numbers being ultimately retained in cardiac tissue, there was no re-increase in SI during our 60 min tracking period. In addition, the likelihood of recirculation contributing to greater retention remains low as most mononuclear cells will home to or remain trapped in organs such as the spleen or liver.\textsuperscript{28} Moreover, as reported recently by Doyle et al.,\textsuperscript{29} differences in retention according to IC injection technique (by single bolus technique vs. by stop-flow technique) are not significant and will likely not overcome the important washout effect after balloon deflation. Thus, our findings corroborate prior reports from both animal and human studies reporting poor cell retention following MPC delivery in infarcted microenvironment (on the order of 1.3–17.8\% of injected cells).\textsuperscript{28–30}

The appropriateness and safety of IC administration of MSC remains disputed. Investigators have reported on the clinical safety and feasibility of MSC IC injection in MI patients.\textsuperscript{9,11} Conversely, Vulliet et al.\textsuperscript{31} reported on the acute embolization of microvessels following IC delivery of MSC, whereas Freyman et al.\textsuperscript{32} documented only transient decreased coronary blood flow (without evidence of microinfarction) combined to greater MSCs engraftment and an improvement in efficacy after IC injection. Alternatively, Perin et al.\textsuperscript{33} recently provided crucial information in a pilot study on the safety of IC delivery of MSCs. It would seem that the issue is not so much the route of administration as it is the rate at which the cell bolus is delivered. Rates of cell administration greater than 1.5 \times 10^{9}/min were associated with an incremental rise in biomarkers of cardiac injury.\textsuperscript{33}

Our inconsistent finding of vessel plugging (not all MSC-injected swine had evidence of distal embolization) points to additional mechanisms of IC-injected MSC for improved retention. Though simple physical characteristics of MPCs (cell size or microvascular...
obstruction) are plausible, one should also consider the contribution of biological processes related to cellular trafficking, i.e. the ability of IC-delivered MPC to home to, adhere to and transmigrate through injured endothelium into the cardiac microenvironment. While speculative, our findings point to the possibility that inflammation following MI could potentiate greater adhesion between circulating or injected MSCs (once exposed to the in vivo milieu) and lead to their progressive cellular impaction and clumping in myocardial vessels. Enhanced MSC adhesion to cardiac microvascular endothelium has been previously described due to the inflammatory state elicited by an acute MI, resulting from greater VCAM-1 expression mediating the cellular interaction. Nevertheless, due to the potential for detrimental effects of acute microinfarction and/or progressive vascular plugging, the IC injection of MSCs in the post-MI setting remains controversial and caution should be exercised when considering this specific route of delivery.

Key limitations of our study need to be considered. in vivo tracking was limited to the early phase (the first pass and the subsequent 60 min) after IC injection. Multipotent progenitor cells were unfractionated and more selected populations [for example, CD34+, CD133+, or MAPCs (multipotent adult progenitor cells)] could have interacted differently with injured myocardium. Only one rate of cell infusion was investigated and cell injection was done on day 3–4 post-MI. Another time window (sequent 60 min) after IC injection. Multipotent progenitor cells (further detailed in Supplementary material online).

In conclusion, our study provides both in vivo evidence of the poor myocardial retention (in the immediate, early phase after IC delivery) of MPCs as well as in vivo proof of a potential deleterious effect of the IC delivery of MSC when administered after recent MI, i.e. vessel plugging through cell impaction and clumping. These findings highlight important efficacy and safety issues to consider for future clinical trials.

Supplementary material

Supplementary material is available at European Heart Journal online.

Funding

This study was supported by grants from the National Institutes of Health: R01-CA-115296 (J.V.F.) and R01 HL078691, HL057263, HL071763, HL080498, and HL083156, and a Leducq Transatlantic Network (R.J.H.).

Conflict of interest: none declared.

References


